Alyeska Investment Group
PRTK

Alyeska Investment Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Alyeska Investment Group’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-483,437
Closed -$4.93M – 535
2018
Q2 		$4.93M Sell
483,437
-943,624
-66% -$10.7M 0.04% 273
2018
Q1 		$18.6M Buy
1,427,061
+287,349
+25% +$4.28M 0.15% 165
2017
Q4 		$20.4M Buy
1,139,712
+223,363
+24% +$4.66M 0.16% 151
2017
Q3 		$23M Buy
916,349
+756,535
+473% +$17.6M 0.17% 168
2017
Q2 		$3.85M Buy
+159,814
New +$3.53M 0.03% 302

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Alyeska Investment Group's PRTK Position: Q3 2018 in Review

Alyeska Investment Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2018, closing a stake of 483,437 shares — an estimated $4.93M sold.

Alyeska Investment Group first reported a position in PRTK in Q2 2017 and held it in 5 quarters. The position peaked at $23M in Q3 2017. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2018.

  • Alyeska Investment Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 483,437 Paratek Pharmaceuticals, Inc. shares in Q3 2018, an estimated $4.93M.
  • Alyeska Investment Group first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 5 quarters.
  • Alyeska Investment Group's Paratek Pharmaceuticals, Inc. position peaked at $23M in Q3 2017.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2018.

Based on Alyeska Investment Group's 13F filing for Q3 2018, filed 14 Nov 2018.